TOP1 and breast cancer: In that respect, it has been shown that around 30 % of BC patients possess amplifications of the TOP1 gene [11] and a clinical trial is currently investigating if increased TOP1 gene copy numbers may be a predictive biomarker for response to irinotecan in BC patients [12].